While multifactorial in origin Cardiac amyloid is a fibrotic process existing in a pretty barren treatment landscape. The amyloid deposits crowd out the myocytes, troponin levels increase screaming heart muscle is struggling, left ventricular becomes enlarged and less compliant, diastolic dysfunction ensues, ejection fraction takes a hit. At one time cardiac transplant was about the only thing that work, everything else amounted to supportive measures.

Dr Jay: “As the Company continues to prioritize its oncology objectives for 2025, we look forward to establishing the right partnership to further the clinical development pathway for leronlimab in the treatment of fibrosis of the liver and potentially other organs, such as the lungs and heart.”

Pulmonary fibrosis is also a killer and dramatically reduces life expectancy. Unmet needs here, expanding market opportunities as the oncology pot continues to simmer. Clearly better days ahead for investors.